MedTrace Logo

Bevacizumab and Carboplatin for Patients With Ovarian Cancer

NCT00744718 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2016-11-16

No results posted yet for this study

Summary

This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients with platin resistant ovarian cancer.

Conditions

Interventions

DRUG

Bevacizumab

Bevacizumab 10 mg/kg every 3 weeks

DRUG

Carboplatin

Carboplatin AUC 5 every 5 weeks

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Anders Jakobsen, MD, DMSc · Department of Oncology, Vejle Hospital

Study Design

Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2015-08-31
Completion
2015-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00744718 on ClinicalTrials.gov